logo
logo
RXST stock ticker logo

RxSight, Inc.

NASDAQ•RXST
CEO: Dr. Ronald M. Kurtz M.D.
板块: Healthcare
行业: Medical - Devices
上市日期: 2021-07-30
RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
联系方式
100 Columbia, Aliso Viejo, CA, 92656, United States
949-521-7830
www.rxsight.com
市值
$302.48M
市盈率 (TTM)
-8.1
26.6
股息率
--
52周最高
$27.13
52周最低
$6.32
52周范围
5%
排名59Top 87.6%
2.2
F-Score
改良版 Piotroski 分析
基于 6 年期基本面
疲弱 • 2.2 / 9 分
评分区间 (0-9)
8-9: 价值优异
6-7: 基本面强劲
4-5: 整体稳健
0-3: 表现疲弱
数据范围: 2020-2025

财务仪表盘

Q4 2025 数据

营业收入

$32.61M+0.00%
近4季度走势

每股收益

-$0.22+0.00%
近4季度走势

自由现金流

$17.09M+0.00%
近4季度走势

2025 Annual 财报亮点

核心亮点

Gross Margin Improvement Gross Profit reached $103.0M, up 4.1%; favorable LAL sales mix improved gross margin to 76.6%.
LAL Utilization Growth LAL sales increased 11,560 units year-over-year, driven by expanding installed base of 1,134 LDD units.
Strong Cash Position Total cash and short-term investments stand at $228.1M as of December 31, 2025, ensuring liquidity.
Adoption Milestones Reached Nearly 300,000 LALs implanted since inception through year-end 2025, validating commercial traction and adoption efforts.

关注风险

Sales Volume Decline Total Sales decreased 3.9% to $134.5M, primarily due to 47% drop in LDD unit sales for the year.
Widening Operating Loss Operating Loss widened 30.7% to $(48.2M) as SG&A expenses increased 11.1% to $112.7M.
Pending Litigation Exposure Facing securities class action and shareholder derivative lawsuits; adverse resolution could materially impact business.
Intense Market Competition Primary competitors (Alcon, J&J) control 75% of U.S. premium IOL market, posing intense competition risk.

前瞻展望

Focus on Revenue Growth Commercial realignment initiatives focus on renewed revenue growth via increased LAL utilization at existing practices.
Increased R&D Investment R&D spending increased 12.2% to $38.5M, targeting clinical outcomes, customer experience, and cost reduction.
Selective International Expansion Planning selective international expansion, holding regulatory approvals in Europe, Canada, Mexico, and Asia markets.
Capital Sufficiency Confirmed Expect current cash reserves of $228.1M to fund operations for at least the next 12 months.

同行对比

营业收入 (TTM)

TCMD stock ticker logoTCMD
$329.52M
+12.5%
KIDS stock ticker logoKIDS
$236.35M
+15.4%
TMCI stock ticker logoTMCI
$212.69M
+1.6%

毛利率 (最新季度)

SMLR stock ticker logoSMLR
91.5%
+0.1pp
DCTH stock ticker logoDCTH
85.5%
+1.9pp
TMCI stock ticker logoTMCI
80.6%
-1.1pp

关键指标

股票代码
市值
市盈率 (TTM)
净资产收益率 (TTM)
负债率
BFLY$967.60M-11.9-35.3%6.9%
SRDX$614.51M-34.8-15.6%19.2%
TCMD$604.28M32.39.3%5.8%

长期趋势

近4季度
营业收入
净利润
经营现金流
4季度营收复合增长率
-4.9%
基本持平
4季度净利润复合增长率
N/M
盈利状态转变
现金流稳定性
25%
现金流需要关注

深度研究

下次财报:2026年5月12日
|
每股收益:-$0.31
|
营业收入:$29.97M
财务数据
电话会议
财务报告
新闻
利润表
资产负债表
现金流量表
财务比率
变化率
利润表
过去12个月
无数据